Direct Answer
Hologic is a leading women's health company with strong positions in breast imaging (3D mammography), molecular diagnostics (Panther platform), and minimally invasive gynecological surgery, navigating a post-COVID revenue normalization while investing in organic growth.
Hologic (HOLX): Women's Health Medical Devices and Diagnostics
Company Snapshot
| Ticker | HOLX |
|---|---|
| Exchange | NASDAQ |
| Sector / Industry | Health Care / Health Care Equipment |
| Headquarters | Marlborough, MA |
| Founded | 1985 |
| Revenue (FY2024 approx.) | ~$3.8B |
| CIK | 0000859737 |
| SEC EDGAR | View filings |
What does Hologic do?
Hologic is a medical technology company focused on improving women's health through diagnostics, medical imaging, and minimally invasive surgical products. Founded in 1985, Hershey was initially focused on bone density measurement before pivoting to breast health imaging. A series of major acquisitions transformed it into a diversified women's health platform.
The company's core products include Genius 3D Mammography systems, the Panther and Panther Fusion molecular diagnostic analyzers, NovaSure endometrial ablation devices, and MyoSure hysteroscopic tissue removal systems. Hologic's fiscal year ends in late September.
Business segments
Hologic reports four segments:
- Diagnostics (~45-50% of revenue): Molecular testing consumables and instruments. The Panther platform (automation-focused, high-throughput) and Panther Fusion (open-architecture, supports multiple assay types) support STI testing (chlamydia, gonorrhea, trichomonas, HPV), respiratory assays (flu, RSV, COVID-19), and other infectious disease testing. Recurring consumable revenue from installed instruments provides predictable base business.
- Breast Health (~30% of revenue): Digital mammography systems, 3D tomosynthesis (Genius 3D), breast biopsy systems, specimen radiography, and service/maintenance contracts on installed base. The shift from 2D to 3D mammography has been a long-running upgrade cycle.
- Surgical (~15% of revenue): NovaSure for endometrial ablation (treatment of heavy menstrual bleeding without hysterectomy) and MyoSure for hysteroscopic myomectomy (fibroid and polyp removal). Both use minimally invasive approaches that have replaced traditional open surgical procedures.
- Skeletal Health (small): Bone density assessment systems (DEXA scanners for osteoporosis screening).
COVID-19 testing and post-pandemic normalization
Hologic's Panther molecular diagnostic platform was deployed at scale for COVID-19 PCR testing during 2020-2022, generating several billion dollars in incremental revenue beyond the company's historical baseline. During fiscal 2021 and 2022, COVID-19 molecular assay revenue alone exceeded $1.5-2B annually, dramatically elevating reported diagnostics segment revenue.
As COVID-19 testing demand returned to endemic levels and rapid antigen tests displaced PCR for routine consumer testing, Hologic's diagnostics revenue contracted significantly. The company worked to reframe investor expectations around a "base business" baseline that excluded COVID-19 tailwind, emphasizing organic growth in non-COVID assays and the expanded instrument installed base that could be leveraged for other test menus.
Acquisitions and capital allocation
Hologic has been an active acquirer. The Cytyc acquisition (2007, ~$6.2B) brought ThinPrep cervical cytology and NovaSure. The Gen-Probe acquisition (2012, ~$3.8B) established the molecular diagnostics platform. More recently, Hologic used COVID-19-generated cash flows to invest in bolt-on acquisitions, R&D, and aggressive share buybacks. The company reduced share count meaningfully through repurchases at various price points through 2022-2024.
Capital allocation priorities have included returning cash to shareholders via buybacks (Hologic does not pay a common stock dividend), investing in product pipeline, and making targeted acquisitions in women's health adjacencies.
Frequently asked questions
How does Hologic make money?
Hologic earns revenue from four primary segments: Diagnostics (roughly 45-50% of revenue, primarily molecular testing instruments and consumables including STI testing and respiratory assays), Breast Health (roughly 30%, mammography systems, 3D tomosynthesis, and service contracts), Surgical (roughly 15%, minimally invasive gynecological procedures using NovaSure endometrial ablation and MyoSure fibroid removal systems), and Skeletal Health (small percentage, bone density assessment). The company benefits from a razor-and-blades model where installed instruments drive recurring consumable revenue.
What happened to Hologic's COVID-19 testing revenue?
Hologic's molecular diagnostics platform (Panther and Panther Fusion analyzers) was deployed extensively for COVID-19 testing during 2020-2022, generating several billion dollars in revenue beyond the company's historical baseline. As COVID-19 testing demand normalized through 2023-2024, Hologic's diagnostics revenue contracted significantly from peak levels. The company guided investors through this normalization, framing the post-COVID baseline as closer to its underlying organic business. Hologic retained expanded installed instrument bases and testing relationships that can be leveraged for non-COVID assays.
What is Hologic's 3D mammography (tomosynthesis) advantage?
Hologic pioneered digital breast tomosynthesis (3DT), marketed as Genius 3D Mammography, which creates a 3D X-ray image of the breast rather than a traditional 2D mammogram. Studies have shown 3D tomosynthesis detects more cancers (higher sensitivity) and produces fewer false positives (higher specificity) than 2D mammography, reducing unnecessary callbacks and biopsies. Hologic holds a strong market position in 3D mammography systems in the United States. The company also offers related products including breast biopsy systems, specimen radiography, and digital pathology solutions.
How did the Cytyc and Gen-Probe acquisitions shape Hologic?
Hologic acquired Cytyc Corporation in 2007 for approximately $6.2B, adding ThinPrep liquid-based Pap smear technology, NovaSure endometrial ablation, and other gynecology products. The Cytyc acquisition transformed Hologic from a smaller mammography company into a diversified women's health company. Gen-Probe was acquired in 2012 for approximately $3.8B, adding the Panther molecular diagnostic platform and a broad menu of sexually transmitted infection assays. Gen-Probe established Hologic's position in molecular diagnostics, which became the largest revenue segment and the foundation for COVID-19 testing capacity during the pandemic.
What are the main risks for Hologic investors?
Key risks include: post-COVID diagnostics revenue normalization creating year-over-year comparisons that appear as decline rather than true organic contraction; competition in molecular diagnostics from larger players like Roche, Abbott, and Danaher; breast imaging market saturation and replacement cycle timing; reimbursement pressure from payers on diagnostic assays; dependence on U.S. market (roughly 70% of revenue); and the challenge of redeploying capital effectively after COVID-19 generated elevated cash flows.